SolasCure aims to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds. Chronic wounds impact over 40 million people worldwide, with care consuming around 10% of health care expenditure in many countries; while spending on advanced wound care products is over £5 billion each year.
These figures continue to grow as prevalence of obesity and diabetes increases. SolasCure’s first product, Aurase® is a hydrogel containing a safe, active, highly-specific enzyme, isolated and cloned from medical maggots. The medical use of Aurase® should lead to faster wound cleaning – promoting better patient outcomes and reduced healthcare costs. SolasCure was born in 2017 as a spin-off from BRAIN, a leading German biotech company, and is currently preparing a clinical study for Aurase to reach market authorisation.